Mylan (MYL) Offering Possible 7.99% Return Over the Next 3 Calendar Days

Mylan's most recent trend suggests a bearish bias. One trading opportunity on Mylan is a Bear Call Spread using a strike $27.00 short call and a strike $32.00 long call offers a potential 7.99% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $27.00 by expiration. The full premium credit of $0.37 would be kept by the premium seller. The risk of $4.63 would be incurred if the stock rose above the $32.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Mylan is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Mylan is bearish.

The RSI indicator is at 24.59 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Mylan

Why Biggest Valuation Gap In 70 Years Is Buying Opportunity
Fri, 08 Mar 2019 16:39:27 +0000
As some stocks get cheaper, and others get pricier, AllianceBernstein offers a compelling case for seeking out low valuation equities right now.

SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party — Courtesy of $1M Pledge from the Mylan Charitable Foundation
Thu, 07 Mar 2019 20:00:00 +0000
HERTFORDSHIRE, England and PITTSBURGH and SAN JUAN, Puerto Rico, March 7, 2019 /PRNewswire/ — A small crowd of SBP staff, AmeriCorps members, Puerto Rico Central Office of Recovery and Reconstruction's Omar J. Marrero, Esq and volunteers from global pharmaceutical company Mylan (MYL) gathered in a quiet backyard in Villa Palmeras to celebrate the homecoming of Hurricane Maria survivor Ms. Sunchy. While Sunchy and her family's recovery may be over, SBP is rebuilding for many other Puerto Rican families thanks to a major gift from the Mylan Charitable Foundation. “Mylan has a long-established commitment to the people of Puerto Rico, having run operations on the island for more than 30 years,” said Mylan CEO Heather Bresch.

Biotech shares continue to fall on FDA uncertainty
Thu, 07 Mar 2019 19:14:51 +0000
FDA chief Scott Gottlieb on Tuesday unexpectedly announced his resignation from the agency. Under Gottlieb's tenure the FDA approved 59 new drugs last year, and a record 971 generic drugs. The biotech sector is on pace for its worst weekly decline since December, weighed down in part by uncertainty following this week's surprise announcement from Food And Drug Administration Commissioner Scott Gottlieb that he will be stepping down next month.

New Research: Key Drivers of Growth for Toll Brothers, Mylan N.V, Eldorado Resorts, Sinclair Broadcast Group, Eldorado Gold, and Pegasystems — Factors of Influence, Major Initiatives and Sustained Production
Thu, 07 Mar 2019 12:25:00 +0000
NEW YORK, March 07, 2019 — In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

US STOCKS-Wall St set for muted open due to lack of fresh catalysts
Wed, 06 Mar 2019 13:59:13 +0000
Wall Street was set to dip at the open on Wednesday in the absence of fresh developments on trade, with investors taking a step back after a strong run in equities since the start of the year. Hopes that the United States and China will end their bitter trade row and a dovish stance on future interest rate hikes by the Federal Reserve has propelled the S&P 500 11 percent higher this year.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.